2 Oct 2023


PDF 1.8 MB

As a leading global contract manufacturer and development service providerwith 15 production sites in Europe and the USA, we offer extensive capabilitiesfor Steriles, Semi-Solids, Solids and Packaging.

Content provided by our supplier

Aenova Holding GmbH

  • DE
  • 2015
    On CPHI since
  • 1000 - 4999
Company types
Contract Service

Other Content from Aenova Holding GmbH (9)

  • News Aenova opens new building for the production of highly potent drugs

    Aenova opened its new building for highly potent active ingredients at the Regensburg site on June 22, 2023. Highly potent drugs against cancer, among other things, are produced in the new production facilities. With a total investment of around 25 million euros at the Regensburg site, Aenova will thus be able to significantly increase its development and production capacities for the increased market demand for highly effective drugs.
  • News Innovative drug formulations make medicines more patient-friendly: Aenova and Galvita enter strategic partnership

    The Aenova Group is a leading global contract manufacturer and development service provider for the pharmaceutical and healthcare industry. As a full service provider, Aenova develops, produces and packages all common dosage forms, product groups and active ingredient classes from pharmaceuticals to dietary supplements for human and animal health. Galvita is an innovative Swiss start-up company specializing in the development of patient-friendly, age-appropriate dosage forms.
  • News Aenova white paper on "Development of highly potent medicines”

    HPAPIs (highly potent active pharmaceutical ingredients), provide precision treatment for cancer, autoimmune disorders, infectious diseases, and other medical conditions. Their safe handling is a challenge for drug manufacturers, who have to meet equipment, environmental and product quality requirements in the production and development of HPAPIs.
  • Brochure AENOVA IP GmbH

    Aenova offers a broad range of license products.
  • News Aenova publishes white paper on the "Safe and efficient handling of high potent drug products"

    High-potent drug products for oncology or hormone therapy will play an important role in innovative drug therapy in the future. The development and production of drugs with high-potent active ingredients is highly complex and often must be implemented with acceleration. Handling of high potent solid dosage forms therefore is a key need of current pharmaceutical development and manufacturing. To ensure safe and efficient handling of high potency products, mastering a holistic production approach is essential. This drives a fast time-to-market for your new high potent product. 
  • Brochure Softgels

    Unique ProductionKnow-How MaximizesMarket Potential
  • News Aenova expands portfolio with innovative technologies

    The development of new drug products for a wide range of therapeutic areas is a rapidly growing market. Therefore, a smart innovation strategy is essential for contract developers and manufacturers. Aenova is expanding its development and production portfolio, particularly in the area of bioavailability of active pharmaceutical ingredients.

  • Brochure VegaGels Chewable Capsules

    Softgel capsules are starting to be widely used not only for pharmaceuticals and food supplements but also for cosmetics, fragrances, general processed foods, and the like.